Stay updated with breaking news from Thomasb cueni. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BusinessWorld By Teodoro B. Padilla Thomas B. Cueni, director general of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), emphasized that vaccine makers are fully committed to transparency in reporting clinical trial results. They likewise support the need to inform the public of what they know, as well as what they donât know about the vaccines in development. âWe must prioritize thorough validation of the results of pre-clinical and clinical trials by independent expert bodies. Only the most rigorous application of science and openness in the regulatory process can ensure that everyone, starting with healthcare workers, has confidence in COVID-19 vaccines once they have been properly approved,â he wrote in an opinion piece ( ....
COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021 miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021 COVAX Announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021 18 December 2020 Reading time: COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors These agreements mean that all COVAX’s 190 participating and eligible economies will be able to access doses to protect vulnerable groups in the first half of 2021. At least 1.3 billion donor-funded doses will be made available to 92 economies eligible for the Gavi COVAX AMC, targeting up to 20% population coverage by the end of the year. ....